{
  "kind": "treatment",
  "slug": "stiripentol-diacomit",
  "type": "medication",
  "name": "Stiripentol",
  "summary": "Stiripentol (Diacomit) is an anticonvulsant used as adjunctive therapy for seizures in Dravet syndrome.",
  "description": "Stiripentol, marketed under the brand name Diacomit, is an oral anticonvulsant approved for use in combination with clobazam to treat seizures associated with Dravet syndrome in patients 2 years of age and older who are taking clobazam. Its mechanism of action is not fully understood but is believed to involve enhancement of GABAergic neurotransmission and inhibition of certain cytochrome P450 enzymes, which increases plasma levels of co-administered antiepileptic drugs. Stiripentol is typically used when seizures are not adequately controlled by other medications.",
  "category": "medications/neurology",
  "tags": [
    "anticonvulsant",
    "antiepileptic",
    "Dravet syndrome",
    "seizure control"
  ],
  "metadata": {
    "drug_classes": [
      "Anticonvulsant",
      "Antiepileptic"
    ],
    "therapeutic_categories": [
      "Neurology"
    ],
    "mechanism_categories": [
      "GABA",
      "Other"
    ],
    "administration_routes": [
      "Oral"
    ],
    "prescription_status": "Prescription only",
    "controlled_substance": false,
    "generic_available": false,
    "brand_names": [
      "Diacomit"
    ],
    "age_groups": [
      "Pediatric",
      "Adult"
    ],
    "treatment_duration": [
      "Long-term maintenance"
    ],
    "specialty_areas": [
      "Neurology",
      "Pediatric neurology"
    ],
    "fda_approval_year": 2018
  },
  "clinical_metadata": {
    "primary_indications": [
      "Seizures"
    ],
    "off_label_uses": [
      "Other refractory epilepsies (limited evidence)"
    ],
    "contraindications": [
      "Hypersensitivity to stiripentol or any formulation components",
      "Concomitant use with drugs highly dependent on CYP3A4 for clearance and have a narrow therapeutic index"
    ],
    "monitoring_required": [
      "Seizure frequency and severity",
      "Weight and appetite (due to anorexia risk)",
      "Signs of sedation when combined with clobazam",
      "Liver function tests and blood counts"
    ],
    "efficacy_rating": {
      "Dravet syndrome": 3
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "stiripentol",
      "Diacomit",
      "antiepileptic",
      "anticonvulsant"
    ],
    "synonyms": [
      "Diacomit",
      "stiripentol powder",
      "stiripentol capsules"
    ],
    "common_misspellings": [
      "stiripentole",
      "stirpentol",
      "stirpentole"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Adjunctive treatment with clobazam for seizures associated with Dravet syndrome in patients 2 years and older"
      ]
    },
    {
      "type": "mechanism",
      "text": "Enhances GABAergic neurotransmission by increasing GABA receptor activity; inhibits several CYP450 enzymes, leading to increased plasma concentrations of co-administered antiepileptic drugs such as clobazam and valproate."
    },
    {
      "type": "dosing",
      "adult": {
        "oral": "Typically 50 mg/kg/day in 2 or 3 divided doses when combined with clobazam."
      },
      "pediatric": {
        "oral": "Typically 50 mg/kg/day in 2 or 3 divided doses when combined with clobazam."
      }
    },
    {
      "type": "dosage_forms",
      "items": [
        "Capsules: 250 mg, 500 mg",
        "Powder for oral suspension: 250 mg, 500 mg"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Reduction in seizure frequency may be seen within days to weeks; long-term use is often required for sustained benefit."
    },
    {
      "type": "adverse_effects",
      "common": [
        "anorexia",
        "weight loss",
        "drowsiness",
        "fatigue",
        "ataxia",
        "nausea"
      ],
      "less_common": [
        "tremor",
        "diplopia",
        "hypotonia"
      ],
      "serious": [
        "neutropenia",
        "hepatic dysfunction",
        "status epilepticus"
      ]
    },
    {
      "type": "warnings",
      "other": [
        "May increase plasma levels of other antiepileptic drugsâ€”dose adjustments may be necessary",
        "Risk of sedation and respiratory depression when used with clobazam",
        "Monitor for weight loss, hepatic impairment, and hematologic abnormalities"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "Clobazam",
          "risk": "Increased sedation and drug levels",
          "action": "Adjust dose as needed"
        },
        {
          "with": "CYP3A4 substrates (narrow therapeutic index)",
          "risk": "Toxicity due to increased levels",
          "action": "Avoid combination"
        },
        {
          "with": "Valproic acid",
          "risk": "Increased adverse effects",
          "action": "Monitor and adjust dose"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "Seizure frequency and control",
        "Weight and nutritional status",
        "Liver function tests",
        "Complete blood counts"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Limited data; potential benefits may outweigh risks in severe epilepsy",
      "lactation": "Unknown if excreted in human milk; caution advised",
      "geriatrics": "Limited data; monitor closely for increased sensitivity"
    },
    {
      "type": "tapering",
      "text": "Gradually reduce dose over at least 2 weeks to avoid seizure exacerbation."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Often reserved for severe, treatment-resistant epilepsy such as Dravet syndrome",
        "Weight loss and appetite suppression are dose-limiting adverse effects",
        "Combination with clobazam requires careful monitoring of sedation"
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "Diacomit Prescribing Information",
          "url": "https://www.accessdata.fda.gov/"
        },
        {
          "label": "NHS - Stiripentol",
          "url": "https://www.nhs.uk/medicines/stiripentol/"
        },
        {
          "label": "PubChem - Stiripentol",
          "url": "https://pubchem.ncbi.nlm.nih.gov/compound/Stiripentol"
        }
      ]
    }
  ],
  "seo": {
    "title": "Stiripentol (Diacomit) - Uses, Dosage, Side Effects, and Warnings",
    "description": "Stiripentol (Diacomit) is an anticonvulsant for Dravet syndrome, used with clobazam. Learn about dosing, side effects, interactions, and monitoring."
  }
}
